Zafgen Announces Transition of Board of Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
FBR Capital Remains Bullish on Zafgen (ZFGN) Following Announced Orphan Designation of Beloranib in EU
September 30, 2015 10:31 AM EDTFBR Capital reiterated an Outperform rating on Zafgen (NASDAQ: ZFGN) following announced orphan designation of beloranib in the EU for the treatment of craniopharyngioma.
Analyst Christopher James commented, "This morning, Zafgen announced that it was granted orphan designation of beloranib in the EU for... More
